-
-
-
-
-
-
-
ImmunityBio reports 700% revenue growth, expands approvals globally
-
-
-
-
-
-
-
Immunitybio Inc (IBRX) PT Raised to $9 at BTIG
-
-
-
-
-
-
-
ImmunityBio reports $113 million revenue, 700% annual increase
-
-
-
-
-
-
-
ImmunityBio gets european drug agency nod for bladder cancer treatment
-
-
-
-
-
-
-
ImmunityBio raises $80 million from institutional investors
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
-
-
-
-
-
-
-
ImmunityBio (IBRX): FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICEĀ® BCG Shortage
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

